Search
Quinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Reviparin
go.drugbank.com/drugs/DB09259Approved[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]
Tetrodotoxin
go.drugbank.com/drugs/DB05232InvestigationalAn aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. … Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.
Categories: Compounds used in a research, industrial, or household settingTenofovir
go.drugbank.com/drugs/DB14126Investigational[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order … [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
International brands: My-B-DenDrotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawn[A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] … Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4).
Products: SPAMODYN TABLET 40MGCrovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Phenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...
Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidMeglumine
go.drugbank.com/drugs/DB09415ApprovedInvestigationalSynonyms: N-methyl-D-glucamineCategories: Compounds used in a research, industrial, or household settingImidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.